Skip to content
Regulatory

FDA Peptide Timeline 2026

The 2026 timeline of FDA action on therapeutic peptides — the April 15 reclassification, the July Pharmacy Compounding Advisory Committee meeting, and the post-PCAC implementation arc.

April 15, 2026 — Reclassification

The FDA published a Federal Register notice removing twelve therapeutic peptides — BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, Epitalon, GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF — from Category 2 of the 503A bulk drug substances evaluation framework. The action moves these compounds to an interim evaluation tier pending final 503A Bulks List placement.

Practical effect: Licensed 503A compounding pharmacies may now legally prepare these peptides under valid patient-specific prescriptions. The previous Category 2 status had operated as a de facto freeze on at-scale compounding.

April 15 to July 23 — Interim window

The 90-day window between reclassification and the PCAC decision is when the supply chain repositions. Compounding pharmacies are credentialing additional state non-resident registrations, hiring peptide-specific pharmacist expertise, and standing up quality protocols ahead of the post-PCAC volume surge. Telehealth brands with GLP-1 prescribing infrastructure are preparing peptide-category expansions for August/September launch.

July 23–24, 2026 — PCAC meeting

The Pharmacy Compounding Advisory Committee will meet to recommend final 503A Bulks List placement for each of the twelve reclassified peptides. PCAC is a 13-member advisory panel; its recommendations are advisory but historically adopted by the FDA with high fidelity.

Three outcomes are possible per peptide: full approval, approval with restrictions, or referral for further study. Full breakdown of likely outcomes →

August 19, 2026 — Overton nomination

President Trump nominated Dr. Heidi Overton, deputy director of the White House Domestic Policy Council, to lead the FDA — his third choice for the post after acting commissioner Kyle Diamantas and former Rep. Brad Wenstrup (R-Ohio) declined. Overton has made no public statements on peptide compounding, the 503A/503B lists, or GLP-1 policy. No hearing date has been set, and Senate HELP chair Bill Cassidy has called her record "alone is almost disqualifying." The 503A bulks-list rulemaking and the undecided 503B GLP-1 exclusion both land on the next commissioner's desk — confirmed or acting. What the nomination means for peptide compounding and the 503A bulks list →

August 19, 2026 — Novo asks FDA to ban semaglutide compounding

Novo Nordisk formally asks the FDA to place semaglutide on the Demonstrable Difficulties for Compounding (DDC) lists (request first filed Oct 2024, Docket FDA-2017-N-2562), joining Eli Lilly's push to ban GLP-1 compounding while both companies' molecules remain central to the compounding-policy fight. Compounded GLP-1 ban coverage →

August – September 2026 — Implementation

Following the PCAC recommendation, the FDA finalizes Bulks List placement. Compounding pharmacies shift from interim-tier to final-list workflows. Telehealth brands launch peptide formularies. Volume surge begins. Counterfeit pressure on the gray market intensifies.

Q4 2026 — Mature market

Post-PCAC retail pricing settles. Direct-to-consumer telehealth pricing emerges in the $60–90/vial range; PCAB-accredited compounders settle in the $100–200/vial range. State-by-state friction points become more visible as regulatory variance is tested by national-scale ordering volume.

Sources we monitor